CRISPR and transposon in vivo screens for cancer drivers and therapeutic targets

CRISPR and transposon in vivo screens for cancer drivers and therapeutic targets

Abstract Human cancers harbor substantial genetic, epigenetic, and transcriptional changes, only some of which drive oncogenesis at certain times during cancer evolution. Identifying the cancer-driver alterations amongst the vast swathes of “passenger” changes still remains a major challenge. Transp...

Full description

Bibliographic Details
Main Authors: Imran Noorani, Allan Bradley, Jorge de la Rosa
Format: Article
Language:English
Published: BMC 2020-08-01
Series:Genome Biology
Online Access:http://link.springer.com/article/10.1186/s13059-020-02118-9
id doaj-c519cefb242f4bac98fccf96700b8a0f
record_format Article
spelling doaj-c519cefb242f4bac98fccf96700b8a0f2020-11-25T03:51:37ZengBMCGenome Biology1474-760X2020-08-0121112210.1186/s13059-020-02118-9CRISPR and transposon in vivo screens for cancer drivers and therapeutic targetsImran Noorani0Allan Bradley1Jorge de la Rosa2Department of Medicine, University of Cambridge School of Clinical Medicine, University of CambridgeDepartment of Medicine, University of Cambridge School of Clinical Medicine, University of CambridgeDepartment of Medicine, University of Cambridge School of Clinical Medicine, University of CambridgeAbstract Human cancers harbor substantial genetic, epigenetic, and transcriptional changes, only some of which drive oncogenesis at certain times during cancer evolution. Identifying the cancer-driver alterations amongst the vast swathes of “passenger” changes still remains a major challenge. Transposon and CRISPR screens in vivo provide complementary methods for achieving this, and each platform has its own advantages. Here, we review recent major technological breakthroughs made with these two approaches and highlight future directions. We discuss how each genetic screening platform can provide unique insight into cancer evolution, including intra-tumoral heterogeneity, metastasis, and immune evasion, presenting transformative opportunities for targeted therapeutic intervention.http://link.springer.com/article/10.1186/s13059-020-02118-9
collection DOAJ
language English
format Article
sources DOAJ
author Imran Noorani
Allan Bradley
Jorge de la Rosa
spellingShingle Imran Noorani
Allan Bradley
Jorge de la Rosa
CRISPR and transposon in vivo screens for cancer drivers and therapeutic targets
Genome Biology
author_facet Imran Noorani
Allan Bradley
Jorge de la Rosa
author_sort Imran Noorani
title CRISPR and transposon in vivo screens for cancer drivers and therapeutic targets
title_short CRISPR and transposon in vivo screens for cancer drivers and therapeutic targets
title_full CRISPR and transposon in vivo screens for cancer drivers and therapeutic targets
title_fullStr CRISPR and transposon in vivo screens for cancer drivers and therapeutic targets
title_full_unstemmed CRISPR and transposon in vivo screens for cancer drivers and therapeutic targets
title_sort crispr and transposon in vivo screens for cancer drivers and therapeutic targets
publisher BMC
series Genome Biology
issn 1474-760X
publishDate 2020-08-01
description Abstract Human cancers harbor substantial genetic, epigenetic, and transcriptional changes, only some of which drive oncogenesis at certain times during cancer evolution. Identifying the cancer-driver alterations amongst the vast swathes of “passenger” changes still remains a major challenge. Transposon and CRISPR screens in vivo provide complementary methods for achieving this, and each platform has its own advantages. Here, we review recent major technological breakthroughs made with these two approaches and highlight future directions. We discuss how each genetic screening platform can provide unique insight into cancer evolution, including intra-tumoral heterogeneity, metastasis, and immune evasion, presenting transformative opportunities for targeted therapeutic intervention.
url http://link.springer.com/article/10.1186/s13059-020-02118-9
work_keys_str_mv AT imrannoorani crisprandtransposoninvivoscreensforcancerdriversandtherapeutictargets
AT allanbradley crisprandtransposoninvivoscreensforcancerdriversandtherapeutictargets
AT jorgedelarosa crisprandtransposoninvivoscreensforcancerdriversandtherapeutictargets
_version_ 1724486545623220224

Similar Items